01Dec
Americas Antitrust Review 2021
Covid-19 has made 2020 into a year like no other with ‘stay at home’ orders and working from home the new normal. Nonetheless, the tech and pharma industries continued to attract immense antitrust scrutiny, with daily reports in the media and pressure from politicians to address what some perceive to be anticompetitive mergers by digital platforms and pharmaceutical companies, even while innovation in both sectors continues at breakneck speed. In this article, we discuss some of the most...
By:
Cooley LLP
Related
The California Supreme Court recently handed down an intriguing decision which casts doubt on – and...
Read More >
The Coronavirus Aid, Relief, and Economic Security (CARES) Act, among other economic stimulus measur...
Read More >
The National Labor Relations Board (NLRB) has been busy the past few weeks. Below are the top five h...
Read More >
U.S. financial services sector M&A picked up in the second half of 2020, in line with the wider U.S....
Read More >
On July 15, 2019, Rhode Island’s Governor signed into law the Rhode Island Noncompetition Agreement...
Read More >
Overview - This report looks at how Joe Biden’s election will impact U.S. and global transactions,...
Read More >